CureVac N.V.
CVAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $535 | $54 | $67 | $103 |
| % Growth | 895.5% | -20.3% | -34.5% | – |
| Cost of Goods Sold | $106 | $124 | $184 | $238 |
| Gross Profit | $429 | -$71 | -$117 | -$135 |
| % Margin | 80.2% | -131.3% | -172.9% | -131.3% |
| R&D Expenses | $153 | $116 | $63 | $816 |
| G&A Expenses | $70 | $76 | $89 | $87 |
| SG&A Expenses | $74 | $76 | $89 | $89 |
| Sales & Mktg Exp. | $4 | $0 | $0 | $2 |
| Other Operating Expenses | $24 | $11 | -$18 | -$628 |
| Operating Expenses | $252 | $204 | $134 | $277 |
| Operating Income | $178 | -$274 | -$249 | -$412 |
| % Margin | 33.2% | -510.1% | -370% | -400.3% |
| Other Income/Exp. Net | $13 | $14 | $0 | -$0 |
| Pre-Tax Income | $191 | -$260 | -$249 | -$412 |
| Tax Expense | $29 | $0 | -$0 | -$1 |
| Net Income | $162 | -$260 | -$249 | -$412 |
| % Margin | 30.3% | -484% | -369.4% | -399.8% |
| EPS | 0.72 | -1.18 | -1.32 | -2.21 |
| % Growth | 161% | 10.6% | 40.3% | – |
| EPS Diluted | 0.72 | -1.18 | -1.32 | -2.21 |
| Weighted Avg Shares Out | 224 | 220 | 189 | 186 |
| Weighted Avg Shares Out Dil | 225 | 221 | 189 | 186 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12 | $17 | $4 | $10 |
| Interest Expense | $0 | $2 | $4 | $10 |
| Depreciation & Amortization | $19 | $23 | $26 | $36 |
| EBITDA | $210 | -$234 | -$209 | -$386 |
| % Margin | 39.2% | -435.5% | -310.6% | -375.3% |